Soleo Health Chief Executive Officer Drew Walk Named to NHIA Board of Directors

Soleo Health, an innovative leader and national provider of complex specialty pharmacy services, announced today the appointment of Chief Executive Officer Drew Walk to the National Home Infusion Association (NHIA) 2023-2024 Board of Directors.

Drew Walk joins a group of seasoned home infusion experts on the NHIA board, an industry governing body. NHIA is the leading industry association providing education, information, advocacy and resources for the nation’s home and alternate site infusion provider community and the manufacturers, suppliers and service companies who support them. As a leading voice for the home infusion industry on Capitol Hill and with the Administration, NHIA advocates for the industry, ensuring that federal policy supports equitable access to the full range of home infusion therapies and related services.

“It is both a privilege and an honor to be asked to serve on NHIA’s Board of Directors alongside industry leaders and individuals who lead well-established and respected companies in the home infusion arena. I am proud to have an opportunity to add my voice to theirs as we work collectively to further the important role home infusion plays for all stakeholders – patients, payors, physicians, health systems and pharmaceutical manufacturers,” Walk said of his Board appointment.

“In my Board position, I hope to advance the key issues we face as an industry and find solutions that assist in enhancing patient care. These include, among others, addressing the changing regulatory landscape and reimbursement environment as well as facilitating technology across all communication channels including patient-provider and patient-pharmacy since the use of telehealth initiatives are on the rise,“ Walk concluded.

Connie Sullivan, BSPharm, NHIA president and chief executive officer, commented on Walk’s Board appointment: “We welcome Drew to the NHIA Board, which we expanded this term to 15 total seats to allow for broader diversification of infusion provider organization representation. Over the course of his career, Drew has worked with various types of healthcare entities which allows him to bring a broad range of experience to all stakeholders. We look forward to Drew’s contributions to our constituents and Board.”

The 2023-2024 Board of Directors will be installed after NHIA’s Annual Conference in Washington, D.C., March 25-29, 2023. Each will serve a three-year term.

Drew Walk has been involved in the home infusion industry since 1985. Trained as a pharmacist, he has held roles of increasing responsibility at health systems, small independent infusion pharmacies and large national providers. This directly speaks to the range and depth of his experience. Walk’s new appointment marks the second time he has served on the NHIA Board, the first being a four-year term from 2010-2014.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”